Cardiol Therapeutics Inc.

TSX:CRDL Stock Report

Market Cap: CA$183.0m

Cardiol Therapeutics Valuation

Is CRDL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRDL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CRDL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CRDL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRDL?

Key metric: As CRDL is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CRDL. This is calculated by dividing CRDL's market cap by their current book value.
What is CRDL's PB Ratio?
PB Ratio16.7x
BookCA$10.43m
Market CapCA$182.97m

Price to Book Ratio vs Peers

How does CRDL's PB Ratio compare to its peers?

The above table shows the PB ratio for CRDL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.3x
DMT Small Pharma
6.3xn/aCA$50.4m
PLTH Planet 13 Holdings
0.9xn/aCA$195.1m
OGI Organigram Holdings
0.8x143.5%CA$220.4m
NGEN NervGen Pharma
17.1xn/aCA$160.2m
CRDL Cardiol Therapeutics
16.7x22.9%CA$183.0m

Price-To-Book vs Peers: CRDL is expensive based on its Price-To-Book Ratio (16.7x) compared to the peer average (6.3x).

Price to Book Ratio vs Industry

How does CRDL's PB Ratio compare vs other companies in the CA Pharmaceuticals Industry?

9 CompaniesPrice / BookEstimated GrowthMarket Cap
AVNT Avant Brands
0.1xn/aUS$4.93m
BZAM BZAM
0.08xn/aUS$4.88m
CPTR Captor Capital
0.07xn/aUS$1.99m
IDVR INDVR Brands
0.1xn/aUS$1.17m
CRDL 16.7xIndustry Avg. 1.0xNo. of Companies12PB00.61.21.82.43+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CRDL is expensive based on its Price-To-Book Ratio (16.7x) compared to the Canadian Pharmaceuticals industry average (1x).

Price to Book Ratio vs Fair Ratio

What is CRDL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRDL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio16.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CRDL's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fennec Pharmaceuticals

US$117.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.50

7D

7.6%

1Y

-44.2%

Medexus Pharmaceuticals

CA$52.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.15

7D

5.4%

1Y

40.5%

Verano Holdings

CA$850.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.32

7D

-12.8%

1Y

-60.6%